Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$7.56
$0.18(2.38%)
At close: 4:00 PM EDT
$7.56
$0.18(2.38%)
Day’s Range― - ―
52-Week Range$2.24 - $12.06
Previous CloseN/A
Volume400.70K
Average Volume (3M)6.43M
Market Cap
$1.64B
Enterprise Value$1.63K
Total Cash (Recent Filing)$201.14M
Total Debt (Recent Filing)$3.68M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Nov 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding171,614,010
10 Day Avg. Volume3,381,155
30 Day Avg. Volume6,434,959
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.38Price Target Upside76.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$4.74M
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway And Low LeverageHigh liquidity and minimal debt give AbSci time to fund clinical and platform work through key readouts without near-term refinancing pressure. This improves strategic flexibility, although it does not remove the need to convert spending into revenue.
Favorable ABS-201 Pharmacokinetics And SafetyThe long half-life and favorable early safety profile could support infrequent dosing, an important product attribute for adherence and differentiation. These findings improve development feasibility, but commercial value still depends on efficacy and later-stage confirmation.
AI Platform Efficiency And Strategic ValidationOrigin’s reported library-size reduction and Lilly’s strategic investment support a potentially differentiated discovery platform and external validation. Together they may improve program productivity and partnership credibility over multiple development cycles.
Bears Say
Very Limited And Declining Revenue ScaleRevenue remains too small to support the operating base, limiting evidence that the collaboration model has achieved repeatable commercial scale. Continued low program revenue could constrain self-funded development and leave AbSci dependent on financing or milestones.
Heavy Cash Burn And Persistent LossesLarge operating and free-cash-flow losses show that research investment is translating into substantial cash consumption rather than internally funded growth. Even with an extended runway, sustained burn can erode flexibility before products or partnerships generate material economics.
Unproven Efficacy And Commercialization Execution RiskABS-201’s evidence remains blinded and directional, with efficacy and durability unresolved; the company also retains development and commercialization responsibility. Failure to confirm meaningful, durable benefit would weaken the lead program and platform payoff.
AbSci News
ABSI FAQ
What was Absci Corp.’s price range in the past 12 months?
Absci Corp. lowest stock price was $2.24 and its highest was $12.05 in the past 12 months.
What is Absci Corp.’s market cap?
Absci Corp.’s market cap is $1.64B.
When is Absci Corp.’s upcoming earnings report date?
Absci Corp.’s upcoming earnings report date is Nov 17, 2026 which is in 85 days.
How were Absci Corp.’s earnings last quarter?
Absci Corp. released its earnings results on Aug 11, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.
Is Absci Corp. overvalued?
According to Wall Street analysts Absci Corp.’s price is currently Undervalued.
Does Absci Corp. pay dividends?
Absci Corp. does not currently pay dividends.
What is Absci Corp.’s EPS estimate?
Absci Corp.’s EPS estimate is -0.19.
How many shares outstanding does Absci Corp. have?
Absci Corp. has 171,614,010 shares outstanding.
What happened to Absci Corp.’s price movement after its last earnings report?
Absci Corp. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went up 0.956%.
Which hedge fund is a major shareholder of Absci Corp.?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.38 (76.92% Upside)
$13.38 (76.92% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $148.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.12%
Trailing 12-Months
Company Description
Absci Corp.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
ABSI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive developments: encouraging interim Phase I safety and PK data for ABS-201, a meaningful strategic investment and collaboration with Eli Lilly, a substantial financing that materially strengthened the balance sheet (cash up ~60% quarter‑over‑quarter), clear near‑term clinical milestones, and notable platform efficiency gains (Atlas/Origin). Key risks and negatives are present but limited: efficacy is not yet unblinded, durability remains to be demonstrated beyond 26 weeks, operating expenses increased modestly (~10.2% R&D; ~8.2% SG&A), and successful commercialization depends on Absci's execution despite Lilly's involvement not conferring program rights. Overall, the highlights meaningfully outweigh the lowlights given the strong cash runway, strategic partner validation, and promising PK/safety profile, though clinical proof of efficacy and durability remain the critical upcoming catalysts.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$13.38
▲(76.92% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.05% Insiders
17.60% Mutual Funds
31.41% Other Institutional Investors
25.49% Public Companies and
Individual Investors